Identity
What is GLP-3 RT?
- Type
- Synthetic peptide (triple-receptor agonist)
- Research code
- LY3437943
- Targets
- GLP-1, GIP, and glucagon receptors
- CAS Number
- 2381089-83-2
- Research family
- Metabolic
- Use classification
- Research Use Only
Science Library · Incretin / triple-receptor
GLP-3 RT the science.
GLP-3 RT corresponds to retatrutide (research code LY3437943), a long-acting peptide studied as a triple agonist of the GLP-1, GIP, and glucagon receptors. Unlike most compounds in this catalog, retatrutide has been evaluated in early human clinical trials in addition to preclinical work. The summary below reflects published research.
View the GLP-3 RT product page →
3 receptors
GLP-1 · GIP · glucagon
LY3437943
Research code
Phase 2
Trial stage
Investigational
Regulatory status
How it works
Mechanism at a glance
Compound
Retatrutide
Targets
GLP-1 + GIP + glucagon
Effect
Metabolic & incretin signaling
Studied in
Obesity trials (Phase 2)
Evidence to date
In vitro
Animal
Human
Evidence to date: preclinical plus early-phase (Phase 2) human trials. Not FDA-approved.
What it is
Retatrutide is a single synthetic peptide engineered to activate three metabolic receptors at once. It is long-acting (studied as a once-weekly injectable in trials) and is investigated in metabolic research as a so-called “triple agonist.” It is an investigational compound — not an approved medicine.
Pathways under study
Its research interest comes from combining three incretin/metabolic pathways:
- GLP-1 receptor — associated with insulin response and satiety signaling.
- GIP receptor — a second incretin pathway studied alongside GLP-1.
- Glucagon receptor — associated with energy expenditure and hepatic metabolism.
What research has explored
Retatrutide has both preclinical and early-phase human research:
- Phase 2 obesity trial (2023). A randomized, placebo-controlled trial published in the New England Journal of Medicine reported substantial body-weight reduction over 48 weeks in adults with obesity, with gastrointestinal side effects typical of the incretin class.
- Metabolic-liver research. Retatrutide has also been studied in randomized trials in metabolic dysfunction-associated steatotic liver disease (MASLD).
These human studies are early-phase and investigational. Retatrutide is not FDA-approved, and this material is supplied for research use only.
Current state of the evidence
Retatrutide is an investigational compound in clinical development. Published evidence includes early-phase human trials in addition to preclinical work, but it is not FDA-approved and no approved indication, dosing, or therapeutic claim applies. GLP-3 RT is supplied strictly as a research material for laboratory investigation.
Compound Snapshot
At a glance
Evidence base
Research maturity
Investigational
Phase 2 human data
Not FDA-approved
Maturity
Clinical (early phase)
Preclinical work plus published Phase 2 human trials; still investigational.
Status
Not FDA-approved
No approved indication, dosing, or therapeutic claim. Supplied for research use only.
Sources & References
Peer-reviewed research and database records
New England Journal of Medicine / PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2023 · PMID 37366315 · DOI 10.1056/NEJMoa2301972 View SourceClinicalTrials.gov
A Study of LY3437943 (Retatrutide) in Participants With Obesity or Overweight
NCT04881760 · U.S. clinical study registry record. View SourcePubChem
Retatrutide compound record
NIH PubChem lookup for molecular identity and structure records. View SourceFor research use only. Not for human or veterinary use. These products have not been evaluated by the FDA. Nothing on this page is medical advice or a therapeutic claim.
Catalog